Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection.

about

Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection.

Item

http://www.wikidata.org/entity/Q52664377

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Effect of antiretroviral thera ...... with primary HIV-1 infection.

@en

Effect of antiretroviral thera ...... with primary HIV-1 infection.

@nl

type

Item

label

Effect of antiretroviral thera ...... with primary HIV-1 infection.

@en

Effect of antiretroviral thera ...... with primary HIV-1 infection.

@nl

prefLabel

Effect of antiretroviral thera ...... with primary HIV-1 infection.

@en

Effect of antiretroviral thera ...... with primary HIV-1 infection.

@nl

P1476

Effect of antiretroviral thera ...... n with primary HIV-1 infection

@en

P2093

Annemieke C Heijboer

http://www.w3.org/2001/XMLSchema#string

Jan M Prins

http://www.w3.org/2001/XMLSchema#string

Marlous L Grijsen

http://www.w3.org/2001/XMLSchema#string

Renate T de Jongh

http://www.w3.org/2001/XMLSchema#string

Robert de Jonge

http://www.w3.org/2001/XMLSchema#string

P2860

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study.

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.

Bone disease in HIV infection: a practical review and recommendations for HIV care providers.

Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study.

Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies.

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.

P304

e0193679

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0193679

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Martin den Heijer

Mariska C Vlot

P577

2018-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29522570

http://www.w3.org/2001/XMLSchema#string

P932

5844537

http://www.w3.org/2001/XMLSchema#string